Deals Shaping The Medical Industry, April 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.
You may also be interested in...
The latest medical device user fee (MDUFA) reports seem to indicate the percentage of premarket applications that receive a major deficiency letter are starting to come back up. US FDA says a key reason for the letters is because of insufficient testing information from device sponsors. The agency offers some steps that sponsors can take to avoid getting one of the dreaded missives.
Sponsors of PMA or HDE-authorized devices can make some modifications in response to COVID-19 without first alerting the US FDA under a recent guidance document.
“Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” FDA says. Warning submitted in March said falsifying data was found in making batch release decisions related to whether certain sterile ophthalmic drugs contained viable microorganisms.